Full-Time

Thought Leader Liaison

Tepezza, Rare Disease

Posted on 5/8/2025

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

Compensation Overview

$195.4k - $226.9k/yr

+ Bonus + Sales-based Incentive Plan

Mid, Senior

Dallas, TX, USA + 1 more

More locations: Oklahoma City, OK, USA

Coverage of South Central Region – Texas and Oklahoma

Category
Customer Success
Strategic Account Management
Sales & Account Management
Required Skills
Sales
Branding/Brand Strategy
Marketing
Requirements
  • Doctorate degree and 2 years of marketing, sales, relevant clinical or medical experience
  • Master's degree and 4 years of marketing, sales, relevant clinical or medical experience
  • Bachelor's degree and 6 years of marketing, sales, relevant clinical or medical experience
  • Associates degree and 10 years of marketing, sales, relevant clinical or medical experience
  • High school diploma / GED and 12 years of marketing, sales, relevant clinical or medical experience
Responsibilities
  • Identify, cultivate and maintain professional relationships and deep engagement of key customers, including opinion leaders (OL), speakers, IDNs, Centers of Excellence and local/regional professional societies
  • Manage and develop relationships with speakers in collaboration with marketing - activities include training, developing and engaging speakers, ensuring speaker compliance and auditing speaker programs
  • Demonstrate excellence in customer-facing stakeholder collaboration – inclusive of sales, patient services, medical science liaisons
  • Determine where customers are in their engagement and advocacy journey with TED and TEPEZZA and help to drive tactics that increase engagement and advocacy
  • Understand and map the local customer experience, including seeing opportunities and barriers, local referral patterns and key relationships
  • Create local initiatives and solutions to address gaps and opportunities in the customer experience
  • Collect and share insights with the internal cross-functional team to inform the brand strategy
  • Participate in cross-functional team meetings ensuring knowledge of key priorities and metrics to help drive TEPEZZA business objectives
  • Coordinate and lead all key customer meetings with the brand team at national and regional conferences
  • Work with local sales team to ensure all local sponsorship conference marketing needs are met related to local tabletop displays and product theatres
  • Partner with sales and marketing to ensure speakers are prepared to execute product theatres at local, regional and national conferences
  • Help marketing identify and secure KOL support on key projects and initiatives across the brand
  • Demonstrate a comprehensive understanding of the disease state, competitive landscape and therapeutic management of Thyroid Eye Disease
  • Operate at the highest standards in alignment with Amgen’s code of business conduct, ensuring all interactions with KOLs are on-label and consistent with commercial, regulatory, and legal guidelines
Desired Qualifications
  • 3-5 years of experience working in Ophthalmology, Endocrinology or Rare Disease in customer facing roles (sales, district manager, medical affairs/MSL, marketing opinion leader management, etc.)
  • Experience developing and executing HCP key customer strategies
  • Relationships with ophthalmology or endocrinology opinion leaders
  • Biotech/pharmaceutical industry experience required
  • Strong relationship management capabilities
  • Ability to understand scientific literature and key publications
  • Excellent organizational skills with keen attention to detail and the abilities to take ownership of issues and to work independently with confidence and to meet deadlines
  • Excellent verbal and written communication skills
  • Ability to work well with all levels of employees and demonstrate strong collaboration skills
  • Ability to work in a fast-paced, dynamic environment
  • Professional, proactive demeanor
  • Strong interpersonal skills

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are medicines made from living organisms. These therapies target conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen stands out from competitors by reinvesting a large portion of its earnings into research and development, ensuring a strong pipeline of new treatments. The goal of Amgen is to improve patient care and address critical health challenges through its innovative therapeutic solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen's investment in AI aligns with trends in biotechnology innovation.
  • Institutional investments indicate strong market confidence in Amgen's growth.
  • FTC clearance of the Horizon merger may ease future regulatory hurdles.

What critics are saying

  • Competitors' AI-driven drug discovery could outpace Amgen's traditional R&D methods.
  • FTC scrutiny of mergers may complicate Amgen's future growth strategy.
  • Advancements in quantum technologies could pose a competitive threat to Amgen.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline of potential new therapies in development.
  • Amgen's acquisition of Horizon Therapeutics enhances its rare disease portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

BioSpace
Sep 19th, 2023
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans

The consent agreement struck between the FTC and Amgen and Horizon Therapeutics could have significant implications for ongoing and future M&A challenges, experts told BioSpace.